• Explore /
  • Poster
  • / A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).

A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).

Abstract Video & Slides Poster

Authors

null

Naval Guastad Daver

The University of Texas MD Anderson Cancer Institute, Houston, TX

Naval Guastad Daver , Abhishek Maiti , David Andrew Sallman , Gail J. Roboz , Melhem M. Solh , Filippo Milano , Stephen Anthony Strickland , Alireza Eghtedar , Steven Brian Kanner , Guy Ledergor , Donna Marcy , Elizabeth Garner , Brian J. Francica , McKay Shaw , Kalin Bird , Jennifer Rattan , Enrique Zudaire , Socorro Portella , Pankit Vachhani , Jae H. Park

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT06128044

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS6586)

DOI

10.1200/JCO.2024.42.16_suppl.TPS6586

Abstract #

TPS6586

Poster Bd #

144b

Abstract Disclosures

Similar Posters

First Author: Jesus G. Berdeja

First Author: Boyu Hu

First Author: Aaron Rapoport

First Author: Frederick L. Locke